Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiSCOVER: Celiprolol for vEDS
NCT05432466Phase 3Recruiting
- Sponsor
- Acer Therapeutics Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vascular Ehlers-Danlos syndrome (VEDS) comparing Celiprolol Arm with Placebo Arm (2 arms). Primary endpoint: Time to first occurrence of a vEDS-related clinical event requiring medical attention at 40 months. Started Nov 2022; status: recruiting.
02
Drugs
celiprolol
03
Conditions
Vascular Ehlers-Danlos syndrome (VEDS)
Beyond the preview
Go deeper on NCT05432466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432466.